Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Open Access
- 1 February 2021
- journal article
- Published by American Diabetes Association in Diabetes Spectrum
- Vol. 34 (1) , 73-75
Abstract
Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the GKeywords
This publication has 11 references indexed in Scilit:
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020Diabetes Care, 2019
- Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinoloneJAAD Case Reports, 2018
- Glucagon-Like Peptide 1 Receptor Agonists for Type 2 DiabetesDiabetes Spectrum, 2017
- Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributorsPatient Preference and Adherence, 2016
- Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting SystemDiabetes Spectrum, 2015
- Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily TherapyClinical Therapeutics, 2015
- Adverse Effects of GLP-1 Receptor AgonistsThe Review of Diabetic Studies, 2014
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2013
- Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1997
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981